Atopic Dermatitis Clinical Trials in Philadelphia, Pennsylvania

7 studies are recruiting for atopic dermatitis in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

   The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Atd002 52019, Philadelphia, Pennsylvania

   Locations

   68 in total

   Run by

   UCB Biopharma SRL

   See if you can join NCT07277660 on ClinicalTrials.gov

2. A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

   The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin. The study is seeking participants who: 1. A…

   Stage

   Phase 2

   Ages

   18 to 64

   Site

   Paddington Testing Co, Inc, Philadelphia, Pennsylvania

   Locations

   23 in total

   Run by

   Pfizer

   See if you can join NCT07216027 on ClinicalTrials.gov

3. FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

   The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in p…

   Stage

   Phase 1

   Ages

   18 to 70

   Site

   Paddington Testing Company, Philadelphia, Pennsylvania

   Locations

   5 in total

   Run by

   Pfizer

   See if you can join NCT06564389 on ClinicalTrials.gov

4. A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

   Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy an…

   Stage

   Phase 3

   Ages

   18 to 63

   Site

   Clinical Research of Philadelphia /ID# 264972, Philadelphia, Pennsylvania

   Locations

   128 in total

   Run by

   AbbVie

   See if you can join NCT06389136 on ClinicalTrials.gov

5. A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

   The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction. This study is seeking participants who: * are 18 years of age or more. …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Paddington Testing Co, Inc, Philadelphia, Pennsylvania

   Locations

   98 in total

   Run by

   Pfizer

   See if you can join NCT05995964 on ClinicalTrials.gov

6. Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

   The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.

   Stage

   Not phased

   Ages

   12 and older

   Site

   Galderma Investigational Site 8559, Philadelphia, Pennsylvania

   Locations

   108 in total

   Run by

   Galderma R&D

   See if you can join NCT06988605 on ClinicalTrials.gov

7. A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

   The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of a single and multiple SC dose of BxC-I17e in patients with moderate to severe atopic dermatitis (AD)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   3 in total

   Run by

   Brexogen Inc.

   See if you can join NCT06055361 on ClinicalTrials.gov